| scholarly article | Q13442814 |
| P2093 | author name string | Xiaojiang Cui | |
| Alice Chung | |||
| William Audeh | |||
| Armando Giuliano | |||
| P2860 | cites work | Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941 | Q24321567 |
| PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer | Q24338724 | ||
| Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
| EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy | Q27824812 | ||
| PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. | Q27824819 | ||
| Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer | Q27824847 | ||
| Lapatinib plus capecitabine for HER2-positive advanced breast cancer | Q27851403 | ||
| NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. | Q27851451 | ||
| Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer | Q27851553 | ||
| Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer | Q27851691 | ||
| Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial | Q27851705 | ||
| Trastuzumab emtansine for HER2-positive advanced breast cancer | Q27851917 | ||
| Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
| Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications | Q27860709 | ||
| Untangling the ErbB signalling network | Q27860884 | ||
| Molecular portraits of human breast tumours | Q28032461 | ||
| Repeated observation of breast tumor subtypes in independent gene expression data sets | Q28131820 | ||
| Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets | Q28140238 | ||
| Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells | Q28201813 | ||
| PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma | Q28243071 | ||
| Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial | Q28254919 | ||
| Genes affecting the cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signaling | Q28289659 | ||
| HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways | Q28299421 | ||
| Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers | Q28375856 | ||
| Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions | Q28609149 | ||
| Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 | ||
| Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer | Q29617440 | ||
| Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer | Q29620676 | ||
| Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer | Q33366766 | ||
| A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine | Q33401523 | ||
| Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. | Q52890142 | ||
| 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. | Q53243856 | ||
| Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining. | Q53664980 | ||
| Tumour biology: herceptin acts as an anti-angiogenic cocktail. | Q53976093 | ||
| Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). | Q53985281 | ||
| Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. | Q54076350 | ||
| Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy. | Q54484711 | ||
| Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. | Q54525297 | ||
| Beta1-integrin circumvents the antiproliferative effects of trastuzumab in human epidermal growth factor receptor-2-positive breast cancer. | Q54711475 | ||
| Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer | Q59567546 | ||
| Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2 | Q62604209 | ||
| Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer | Q71059676 | ||
| Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies | Q72228246 | ||
| Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers | Q74195368 | ||
| NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer | Q77626728 | ||
| CD4+CD25+ regulatory T-cell frequency in HER-2/neu (HER)-positive and HER-negative advanced-stage breast cancer patients | Q80249436 | ||
| Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer | Q82892087 | ||
| Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines | Q83722585 | ||
| HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy | Q83890396 | ||
| Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network | Q40093663 | ||
| Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance | Q40109415 | ||
| Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. | Q40144433 | ||
| Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor | Q40247935 | ||
| Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts | Q40318915 | ||
| Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells | Q40321992 | ||
| Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells | Q40344963 | ||
| Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells | Q40344999 | ||
| Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. | Q40461355 | ||
| The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. | Q40571024 | ||
| Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease | Q40630247 | ||
| Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance | Q40718678 | ||
| Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. | Q40866492 | ||
| The extracellular domain of HER2/neu is a potential immunogen for active specific immunotherapy of breast cancer | Q41720584 | ||
| Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer | Q42508698 | ||
| Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers | Q42521911 | ||
| Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action | Q42523855 | ||
| Analysis of integrin beta4 expression in human breast cancer: association with basal-like tumors and prognostic significance | Q42524837 | ||
| Phase I Study of Everolimus Plus Weekly Paclitaxel and Trastuzumab in Patients With Metastatic Breast Cancer Pretreated With Trastuzumab | Q42848146 | ||
| Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study | Q43121691 | ||
| Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. | Q43290574 | ||
| Heregulin-dependent translocation and hyperphosphorylation of ErbB-2. | Q43663421 | ||
| Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer | Q43937165 | ||
| Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth | Q44120544 | ||
| The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition | Q44406747 | ||
| TGFalpha expression impairs Trastuzumab-induced HER2 downregulation | Q45286133 | ||
| Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs | Q46227342 | ||
| Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. | Q46246951 | ||
| Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study | Q46256397 | ||
| Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients | Q46464385 | ||
| HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues | Q47612892 | ||
| Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/CAP criteria. | Q48001325 | ||
| Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis. | Q52572763 | ||
| Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies | Q33593016 | ||
| The multiple roles of PTEN in tumor suppression | Q33849727 | ||
| ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling | Q33886341 | ||
| Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase | Q34323951 | ||
| Lung cancer: intragenic ERBB2 kinase mutations in tumours | Q34354426 | ||
| Engineered antibody Fc variants with enhanced effector function | Q34424958 | ||
| Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake | Q34436612 | ||
| A system for quantifying dynamic protein interactions defines a role for Herceptin in modulating ErbB2 interactions | Q34587922 | ||
| Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers | Q34679149 | ||
| Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor | Q34759230 | ||
| Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate | Q34880994 | ||
| Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. | Q35170258 | ||
| Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance | Q35783451 | ||
| Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation | Q35889621 | ||
| Lapatinib for advanced or metastatic breast cancer | Q35913209 | ||
| A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer | Q36095920 | ||
| The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review | Q36650719 | ||
| The effects of trastuzumab on the CD4+CD25+FoxP3+ and CD4+IL17A+ T-cell axis in patients with breast cancer | Q37160694 | ||
| Unraveling the biologic and clinical complexities of HER2. | Q37308767 | ||
| The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies | Q37326072 | ||
| Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2. | Q37375540 | ||
| Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells | Q37456176 | ||
| Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes | Q37457262 | ||
| Prognostic value of basal phenotype in HER2-overexpressing breast cancer | Q37924154 | ||
| Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study | Q37989260 | ||
| Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway | Q38363956 | ||
| Antitumor effect of the mTOR inhibitor everolimus in combination with trastuzumab on human breast cancer stem cells in vitro and in vivo | Q39366450 | ||
| HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy | Q39368710 | ||
| Mechanism of resistance to trastuzumab and molecular sensitization via ADCC activation by exogenous expression of HER2-extracellular domain in human cancer cells | Q39371209 | ||
| Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy | Q39381586 | ||
| Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin). | Q39674865 | ||
| Breast tumor cells isolated from in vitro resistance to trastuzumab remain sensitive to trastuzumab anti-tumor effects in vivo and to ADCC killing | Q39865080 | ||
| Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity | Q39908130 | ||
| Trastuzumab decreases the number of circulating and disseminated tumor cells despite trastuzumab resistance of the primary tumor | Q40032572 | ||
| Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer | Q40073275 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 223-232 | |
| P577 | publication date | 2013-08-01 | |
| P1433 | published in | Clinical Breast Cancer | Q332245 |
| P1476 | title | Current status of anti-human epidermal growth factor receptor 2 therapies: predicting and overcoming herceptin resistance | |
| P478 | volume | 13 |
| Q54977394 | A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) induced significant apoptosis of pancreatic cells which was enhanced by erlotinib and ibrutinib. |
| Q96431012 | A self-sustaining endocytic-based loop promotes breast cancer plasticity leading to aggressiveness and pro-metastatic behavior |
| Q38681576 | Advances in systemic therapy for metastatic breast cancer: future perspectives. |
| Q60952626 | CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease |
| Q40457683 | Characterizing CD137 upregulation on NK cells in patients receiving monoclonal antibody therapy. |
| Q37496378 | Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurrent or metastatic breast cancer: results from a Phase II, single-arm, |
| Q41734074 | Dendrimers as Nanocarriers for Nucleic Acid and Drug Delivery in Cancer Therapy. |
| Q36312110 | Distinct ErbB2 receptor populations differentially interact with beta1 integrin in breast cancer cell models |
| Q38615197 | HER3/ErbB3, an emerging cancer therapeutic target |
| Q26851827 | Identifying and targeting tumor-initiating cells in the treatment of breast cancer |
| Q36843741 | Is the skin a sanctuary for breast cancer cells during treatment with anti-HER2 antibodies? |
| Q37528915 | Long-range regulators of the lncRNA HOTAIR enhance its prognostic potential in breast cancer |
| Q41050362 | MPZL1 forms a signalling complex with GRB2 adaptor and PTPN11 phosphatase in HER2-positive breast cancer cells |
| Q64244173 | PRMT5 Associates With the FOXP3 Homomer and When Disabled Enhances Targeted p185 Tumor Immunotherapy |
| Q39701009 | Pertuzumab and trastuzumab: the rationale way to synergy |
| Q38838851 | Phosphorylated ribosomal S6 (p-rpS6) as a post-treatment indicator of HER2 signalling targeted drug resistance |
| Q38680412 | Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression |
| Q38266276 | The extracellular matrix modulates the hallmarks of cancer |
| Q36749041 | The voltage gated Ca(2+)-channel Cav3.2 and therapeutic responses in breast cancer |
| Q34268618 | Therapeutic Considerations in Treating HER2-Positive Metastatic Breast Cancer |
| Q57295430 | Ultrasmall targeted nanoparticles with engineered antibody fragments for imaging detection of HER2-overexpressing breast cancer |
| Q64121737 | Utilization of NGS technologies to investigate transcriptomic and epigenomic mechanisms in trastuzumab resistance |
Search more.